GSTM1 and anemia (phenotype): An analysis of other clinical characteristics showed that stage III-IV patients had markedly abnormal levels of albumin, hemoglobin (Hb), β2-microglobulin (BMG), and lactate dehydrogenase (LDH), indicating malnutrition, severe anemia, and an increased tumor burden in advanced-stage patients.